This therapeutically relevant finding suggests that LDLR-positive tumour cells are more likely to be located within the penetration distance of nanoparticles upon extravasation from the bloodstream and will therefore potentially benefit from such future therapeutic targeting. The gene discussed is LDLR; the disease is neoplasm.